Pharmacotherapy Prescribing Pattern and the Adherence Level to Iron Chelation Therapy in Thalassemia

Key facts

Sponsor

Reem Ali Shaker

Principal Investigator

Fadhil A Riziji, PhD

Kufa university/ faculty of pharmacy

Enrollment

199 target

Eligibility

3-55 years · All sexes

Timeline

2023 – 2024

Study locations (1)

• AL Zahar teaching Hospital, Najaf, Iraq

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07338344
  Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
  Rongrong Liu
• RECRUITINGNANCT07112703
  Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia Major
  Rawan Mohammed Khairy Mostafa Elsawy
• RECRUITINGPHASE3NCT06609226
  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
  Novo Nordisk A/S
• RECRUITINGNANCT06931912
  Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT06657391
  Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
  Rongrong Liu
• ENROLLING BY INVITATIONNCT07003269
  Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT
  Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
• ACTIVE NOT RECRUITINGNCT06596642
  A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
  Bristol-Myers Squibb
• RECRUITINGPHASE1NCT06655662
  Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
  Shenzhen Hemogen

See all trials for Thalassemia →